Incyte announced early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors.
The Northwell Cancer Institute has unveiled its Center for Women’s Cancer at the R.J. Zuckerberg Cancer Center.
Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The European Union, in coordination with the European Health and Digital Executive Agency, has launched DISARM, a Horizon Europe Innovation Action project that brings together 28 partners from 12 countries, including 10 EU Member States, the UK, and Canada.
Research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer. The discovery provides a novel therapeutic target that could potentially make ovarian and other cancers more sensitive to immunotherapies.
Kimberly Leslie, a professor at the University of New Mexico Comprehensive Cancer Center, was awarded a 5-year, $12.9 million grant from NCI. Leslie and her research team, which includes scientists from the Universities of Iowa, Utah, Kansas, Virginia, and California at San Diego, will study all available hormonal regimens to prevent and treat endometrial cancer.
Targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer, according to research by Wistar Institute scientists.
The FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an investigational folate receptor alpha-directed, TOPO1-inhibitor antibody-drug conjugate, for the treatment of adult patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.
